Dainippon Sumitomo hit by Asian trial setback for lurasidone
This article was originally published in Scrip
Executive Summary
Dainippon Sumitomo Pharma's (DSP) plans for a Japanese approval filing for the atypical antipsychotic lurasidone have been set back by the results of an Asian Phase III trial for schizophrenia in which the molecule missed its primary endpoint.